Medical Training Application Service Research Medical Training Application Service RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Genes, Vol. 14, Pages 637: Genome-Wide Association Study for Grain Protein, Thousand Kernel Weight, and Normalized Difference Vegetation Index in Bread Wheat (Triticum aestivum L.)
Singh Gyanendra Singh Genomic regions governing grain protein content (GPC), 1000 kernel weight (TKW), and normalized difference vegetation index (NDVI) were studied in a set of 280 bread wheat genotypes. The genome-wide association (GWAS) panel was genotyped using a 35K Axiom array and phenotyped in three environments. A total of 26 marker-trait associations (MTAs) were detected on 18 chromosomes covering the A, B, and D subgenomes of bread wheat. The GPC showed the maximum MTAs (16), followed by NDVI (6), and TKW (4). A maximum of 10 MTAs was located on the B subgenome, whereas, 8 MTAs each were mapped on the A and...
Source: Genes - March 3, 2023 Category: Genetics & Stem Cells Authors: Gopalareddy Krishnappa Hanif Khan Hari Krishna Narayana Bhat Devate Satish Kumar Chandra Nath Mishra Om Parkash Sachin Kumar Monu Kumar Harohalli Masthigowda Mamrutha Gyanendra Pratap Singh Gyanendra Singh Tags: Article Source Type: research

Genes, Vol. 14, Pages 579: Estimates of Genomic Heritability and the Marker-Derived Gene for Re(Production) Traits in Xinggao Sheep
This study estimated the genetic parameters for four traits to explore the genetic mechanisms underlying the variation, and we performed genome-wide association study (GWAS) tests on a small sample size to identify novel marker trait associations (MTAs) associated with prolificacy and growth. We detected two suggestive significant single-nucleotide polymorphisms (SNPs) associated with LS and eight significant SNPs for BWT, WWT, and ADG. These candidate loci and genes also provide valuable information for further fine-mapping of QTLs and improvement of reproductive and productive traits in sheep. (Source: Genes)
Source: Genes - February 25, 2023 Category: Genetics & Stem Cells Authors: Zaixia Liu Shaoyin Fu Xiaolong He Xuewen Liu Caixia Shi Lingli Dai Biao Wang Yuan Chai Yongbin Liu Wenguang Zhang Tags: Article Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research

Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer?
CONCLUSIONS: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor + hormone therapy. The CDK4/6 inhibitor + hormone therapy is also suitable for patients previously treated with mTOR inhibitor + exemestane. Despite the retrospective and single-center study design, these findings provide useful information for treatment selection in clinical practice.PMID:36823129 | DOI:10.1272/jnms.JNMS.2023_90-205 (Source: Journal of Nippon Medical School)
Source: Journal of Nippon Medical School - February 23, 2023 Category: Universities & Medical Training Authors: Satoko Nakano Akemi Mibu Shunsuke Kato Shigeo Yamaguchi Yuna Suzuki Kaoru Tanimura Masataka Sano Source Type: research